13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
|
Name |
WKN |
Börse |
Kurs |
Datum/Zeit |
Diff. |
Diff. % |
Geld |
Brief |
Erster |
Schluss |
|
SANOFI SA INHABER EO 2 |
920657 |
Xetra |
88,600 |
28.05.24 17:35:43 |
-1,280 |
-1,42% |
0,000 |
0,000 |
89,940 |
89,880 |
|
Regeneron Pharmaceuticals |
881535 |
NASDAQ |
969,000 |
28.05.24 21:19:17 |
-16,020 |
-1,63% |
967,460 |
969,330 |
974,860 |
985,020 |